CAR-T therapy for myeloma shows promise in early trial

NCT ID NCT04318327

Terminated Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 10, 2026 · Updated 2 times

Summary

This early-stage study tested a new type of immunotherapy called CAR-T cells that target a protein called BCMA on multiple myeloma cells. The treatment involved taking a patient's own immune cells, engineering them to attack the cancer, and infusing them back. The study included 96 adults with multiple myeloma that had not responded to at least two prior treatments. The trial was terminated early, but researchers collected data on safety and how well the therapy worked.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

plasma cell myeloma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MULTIPLE MYELOMA

Contacts and locations

Locations

Beth Israel Deaconess Medical Cente

Boston, Massachusetts, 02215, United States
Dana Farber Cancer Institute

Boston, Massachusetts, 02215, United States
Medical College of Wisconsin

Milwaukee, Wisconsin, 53226, United States
Novartis Investigative Site

Melbourne, Victoria, 3004, Australia
Novartis Investigative Site

Ramat Gan, 5265601, Israel
Novartis Investigative Site

Tel Aviv, 6423906, Israel
Novartis Investigative Site

Singapore, 119074, Singapore
Novartis Investigative Site

Singapore, 169608, Singapore
Uni of Chi Medi Ctr Hema and Onco

Chicago, Illinois, 60637, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.